AR表达在三阴性乳腺癌中的研究进展

范 佳婧1, 赵海 宁*2
1、青海大学临床医学院
2、青海大学附属医院

摘要


三阴性乳腺癌（Triple-negative breast cancer，TNBC）由于其固有的侵袭性临床特征和缺乏公认的治疗分子靶点，且预后差，一直是研究的热点和难点。近年来研究表明，雄激素受体（adrenal receptor，AR）作为细胞核类固醇受体家族成员，在TNBC中高表达，与TNBC的发生、发展紧密相关，并有望成为其预后判断的分子标志物和治疗的新靶点。本文总结了AR在TNBC中的最新研究进展，以期为未来研究提供新思路。

关键词


乳腺肿瘤；三阴性乳腺癌；雄激素受体

全文:

PDF


参考


[1]Hackbart H, Cui X, Lee JS. Androgen receptor in breast cancer and its clinical implication. Transl Breast Cancer Res. 2023;4:30. doi:10.21037/tbcr-23-44

[2]Prutianu I, Giuşcă SE, Gafton B, et al. Triple-negative breast cancer: from classical clinicopathological features to androgen receptor profile. Rom J Morphol Embryol. 2024;65(2):209-216. doi:10.47162/RJME.65.2.07

[3]Spurnić I, Šušnjar S, Jovanić I, et al. The Diagnostics of Disease Relapse Within Five-Year Follow-Up and the Role of Androgen Receptor Expression in Patients with Early Triple-Negative Breast Cancer. Diagnostics (Basel). 2025;15(6):692. Published 2025 Mar 11. doi:10.3390/diagnostics15060692

[4]Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. Am J Cancer Res. 2014;4(4):353-368. Published 2014 Jul 16.

[5]Li M, Zhou S, Lv H, Cai M, Shui R, Yang W. Neoadjuvant chemotherapy response in androgen receptor-positive triple-negative breast cancer: potential predictive biomarkers and genetic alterations. Breast Cancer Res. 2025;27(1):41. Published 2025 Mar 20. doi:10.1186/s13058-025-01994-y

[6]Xu F, Xu K, Fan L, et al. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer. Chin Med J (Engl). 2024;137(3):338-349. doi:10.1097/CM9.0000000000002930

[7]Hon JD, Singh B, Sahin A, et al. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864-1872. Published 2016 Sep 1.

[8]Bando Y, Kobayashi T, Miyakami Y, et al. Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy. J Med Invest. 2021;68(3.4):213-219. doi:10.2152/jmi.68.213

[9]Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-5540. doi:10.1158/1078-0432.CCR-13-0799

[10]Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016;37(1):3-15.

[11]骆广涛，汤为香，叶元滋，等.雄激素受体在三阴型乳腺癌中的研究进展[J].临床与实验病理学杂志，2023，39（08）：977-980.DOI：10.13315/j.cnki.cjcep.2023.08.017

[12]Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102-110. doi:10.1016/j.ctrv.2018.06.005

[13]Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta. 2010;1803(6):641-649. doi:10.1016/j.bbamcr.2009.11.012

[14]Jin HJ, Kim J, Yu J. Androgen receptor genomic regulation. Transl Androl Urol. 2013;2(3):157-177. doi:10.3978/j.issn.2223-4683.2013.09.01

[15]Khadela A, Chavda VP, Soni S, Megha K, Pandya AJ, Vora L. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. Cancers (Basel). 2022;15(1):233. Published 2022 Dec 30. doi:10.3390/cancers15010233

[16]Mi Y, Wang X, Song H, et al. circEFR3A promotes breast cancer progression by sponging miR-590-3p to upregulate androgen receptor expression. Oncol Lett. 2025;30(3):446. Published 2025 Jul 17. doi:10.3892/ol.2025.15192

[17]Hu Y, Bian J, Chen W, et al. Androgen receptor-induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p-CCR5 axis. J Biol Chem. 2025;301(4):108428. doi:10.1016/j.jbc.2025.108428

[18]You CP, Tsoi H, Man EPS, Leung MH, Khoo US. Modulating the Activity of Androgen Receptor for Treating Breast Cancer. Int J Mol Sci. 2022;23(23):15342. Published 2022 Dec 5. doi:10.3390/ijms232315342

[19]Vtorushin S, Dulesova A, Krakhmal N. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. J Zhejiang Univ Sci B. 2022;23(8):617-624. doi:10.1631/jzus.B2200113

[20]Hanamura T, Kitano S, Kagamu H, et al. Correction: Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment. Breast Cancer Res. 2023;25(1):28. Published 2023 Mar 20. doi:10.1186/s13058-023-01637-0

[21]Anestis A, Sarantis P, Theocharis S, et al. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145(5):1221-1233. doi:10.1007/s00432-019-02872-9

[22]Joshi S, Garlapati C, Nguyen T, et al. C/EBPβ increases tumor aggressiveness by enhancing KIFC1 expression in androgen receptor negative triple negative breast cancer. Cell Commun Signal. 2025;23(1):255. Published 2025 May 30. doi:10.1186/s12964-025-02243-7

[23]Yamaguchi-Tanaka M, Takagi K, Sato A, et al. Regulation of Stromal Cells by Sex Steroid Hormones in the Breast Cancer Microenvironment. Cancers (Basel). 2024;16(23):4043. Published 2024 Dec 2. doi:10.3390/cancers16234043

[24]Haruna M, Daramola AO, Awolola NA, Badr NM, Banjo AAF, Shaaban A. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria. Ecancermedicalscience. 2022;16:1452. Published 2022 Oct 3. doi:10.3332/ecancer.2022.1452

[25]Dai C, Ellisen LW. Revisiting Androgen Receptor Signaling in Breast Cancer. Oncologist. 2023;28(5):383-391. doi:10.1093/oncolo/oyad049

[26]黄钱，甘淋.雄激素受体在三阴性乳腺癌中的研究进展[J].实用医学杂志，2019，35（02）：318-321.

[27]Dogra A, Krishna V, Doval DC, Mehta A. Androgen receptor expression in triple negative breast cancer: A report from a tertiary care center. J Cancer Res Ther. 2025;21(3):551-557. doi:10.4103/jcrt.jcrt_461_24

[28]Crespo B, Illera JC, Silvan G, et al. Androgen and Estrogen β Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines. Int J Mol Sci. 2024;25(3):1471. Published 2024 Jan 25. doi:10.3390/ijms25031471

[29]Funasaka C, Kogawa T, Sakamoto N, et al. The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer. Cancer Treat Res Commun. Published online May 16, 2025. doi:10.1016/j.ctarc.2025.100941


Refbacks

  • 当前没有refback。